BG
PRME icon

Bollard Group’s Prime Medicine PRME Stock Holding History

Bollard Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558K Sell
151,136
-210,000
-58% -$697K 0.02% 129
2026
Q1 		$1.26M Hold
361,136
– – 0.04% 102
2025
Q4 		$1.25M Hold
361,136
– – 0.03% 101
2025
Q3 		$2M Hold
361,136
– – 0.05% 90
2025
Q2 		$892K Hold
361,136
– – 0.02% 124
2025
Q1 		$719K Hold
361,136
– – 0.02% 121
2024
Q4 		$1.05M Hold
361,136
– – 0.03% 104
2024
Q3 		$1.4M Hold
361,136
– – 0.04% 107
2024
Q2 		$1.86M Hold
361,136
– – 0.05% 85
2024
Q1 		$2.53M Hold
361,136
– – 0.08% 74
2023
Q4 		$3.2M Buy
+361,136
New +$2.78M 0.11% 63

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Bollard Group's PRME Position: Q2 2026 in Review

Bollard Group reduced its Prime Medicine (PRME) stake by 58% in Q2 2026, selling an estimated $697K and leaving 151,136 shares worth $558K. The position accounts for 0.02% of the portfolio, ranked #129.

Bollard Group first reported a position in PRME in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.2M in Q4 2023. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Bollard Group held 151,136 shares of Prime Medicine worth $558K as of Q2 2026.
  • Bollard Group sold 210,000 Prime Medicine shares in Q2 2026, an estimated $697K.
  • Prime Medicine made up 0.02% of Bollard Group's portfolio in Q2 2026, its #129 holding.
  • Bollard Group first reported a position in Prime Medicine in Q4 2023 and has held it in 11 quarters since.
  • Bollard Group's Prime Medicine position peaked at $3.2M in Q4 2023.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Bollard Group's 13F filing for Q2 2026, filed 12 Aug 2026.